RxDoctor Payments Data

Jane Davidson

Physician Assistant · la Jolla, CANPI 1881701787

Payments from drug & device makers

$18,661in general payments, 2019–2025

Across 957 payments — averaging $19.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$8K
  • Pfizer$1K
  • Lilly USA, LLC$867
  • Biohaven Pharmaceuticals, Inc.$826
  • Biohaven Pharmaceutical Holding Company Ltd.$786
  • Teva Pharmaceuticals USA, Inc.$751
  • plus $7K from 39 others

What the payments were for

  • Consulting fees$3752%
  • Travel & lodging$50%
  • Food & beverage$18,25498%
  • Education$270%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,661 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$747,024
Medicare patients
269
Services billed
96,467

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate85$125,252
Aimovig AutoinjectorErenumab-Aooe65$66,426
UbrelvyUbrogepant27$43,381
QuliptaAtogepant39$42,638
Ajovy AutoinjectorFremanezumab-Vfrm30$31,865
Emgality PenGalcanezumab-Gnlm28$19,483
Sumatriptan Succinate122$6,393
Topiramate50$2,908
Eletriptan HbrEletriptan Hydrobromide32$2,453
Amitriptyline Hcl107$2,285
Memantine Hcl19$1,147
Gabapentin49$964
Propranolol Hcl ErPropranolol Hcl13$756
Memantine Hcl ErMemantine Hcl20$732
RizatriptanRizatriptan Benzoate37$607

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$1,097$125,25285 claims
AbbVieUbrelvy, Qulipta$7,677$86,01966 claims
Upsher-smith Laboratories LLCTopiramate$269$2,90850 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in la Jolla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →